Ligand News and Research

RSS

Researchers design ProAgio protein that may potentially treat cancer, other illnesses

A protein designed by researchers at Georgia State University can effectively target a cell surface receptor linked to a number of diseases, showing potential as a therapeutic treatment for an array of illnesses, including cancer, according to the research team.

1 Jun 2016

SBP scientists discover new regulator of immune responses

Research led by scientists at the Sanford Burnham Prebys Medical Discovery Institute has identified a new regulator of immune responses. The study, published recently in Immunity, sheds new light on why T cells fail to clear chronic infections and eliminate tumors.

26 May 2016

Cornell researchers develop nanoparticle-based drug delivery mechanism for combination cancer therapy

A team of researchers from Cornell University in Ithaca, New York demonstrated a drug delivery mechanism that utilizes two independent vehicles, allowing for delivery of chemically and physically dis-tinct agents.

23 May 2016

Two-way communication between cancer cells may be key to tumor metastasis

Two-way communication between cancer cells appears to be key to their becoming motile, clustering and spreading through metastasis, according to Rice University scientists.

21 May 2016

T cell gives precise mechanical tugs to detect friends and foes

T cells, the security guards of the immune system, use a kind of mechanical "handshake" to test whether a cell they encounter is a friend or foe, a new study finds.

6 May 2016

Bim protein may hold clue for immunotherapy response in metastatic melanoma patients

A protein called Bim may hold the clue to which patients may be successful on immunotherapy for metastatic melanoma, according to the results of a study by Mayo Clinic researchers led by senior author Haidong Dong, M.D., Ph.D., and published online in the May 5 edition of JCI Insight.

6 May 2016

Snapshots of NMDA receptor activation may help in novel drug design

Structural biologists at Cold Spring Harbor Laboratory and Janelia Research Campus/HHMI, have obtained snapshots of the activation of an important type of brain-cell receptor. Dysfunction of the receptor has been implicated in a range of neurological illnesses, including Alzheimer's disease, Parkinson's disease, depression, seizure, schizophrenia, autism, and injuries related to stroke.

3 May 2016

Predictive statistical approach opens door to development of more effective therapies for breast cancer

Designing effective new drugs, especially drugs to fight cancer, demands that you know as much as you can about the molecular workings of cancer growth. Without that, it's like planning to fight a war against an enemy you've never seen.

29 Apr 2016

Researchers reveal how bile component taurine attracts Vibrio cholera

A group of researchers from Osaka University, Hosei University, and Nagoya University have revealed the molecular mechanism that Vibrio cholerae, the etiological agent of cholera, is attracted by bile. This group has also successfully detected the ligand binding to the bacteria chemoreceptor in vivo for the first time. These results may significantly advance research on mechanism and control of V. cholerae.

26 Apr 2016

New molecule-building method may have great impact on pharmaceutical industry

Scientists at The Scripps Research Institute (TSRI) have devised a new molecule-building method that is likely to have a major impact on the pharmaceutical industry and many other chemistry-based enterprises.

22 Apr 2016

Scientists examine PD-1-expressing regulatory T cells in aggressive brain cancer

Immunotherapy represents an exciting advance in cancer treatment that harnesses the immune system to seek and destroy cancer cells.

22 Apr 2016

Researchers find mechanism behind pancreatic cancer cells' resistance to certain drugs

Pancreatic cancer is on track to become the second leading cause of cancer-related deaths by 2020. These statistics are due, in part, to pancreatic cancer's resistance to most targeted cancer therapies. Working with pancreatic cancer cells, researchers have now found a mechanism that could be responsible for the cancer's resistance to at least one targeted approach.

19 Apr 2016

Researchers use BMG LABTECH's microplate readers to measure binding events in kinetic over minutes

Single reading events of a signaling molecule at a given time should no longer be considered as the only insightful indicator to predict the usefulness of a new drug candidate.

From BMG LABTECH GmbH 19 Apr 2016

HLA-C/KIR genotype linked to HBeAg-positive HBV interferon response

The human leucocyte antigen-C and killer immunoglobin-like receptor genotypes are associated with response to interferon-based therapy in patients with chronic hepatitis B virus infection positive for hepatitis B e antigen, say researchers.

13 Apr 2016

Flexible ramp scripting interface added for BioScope Resolve BioAFM

At the 7th AFM BioMed Conference, Bruker’s Nano Surfaces Division today announced the release of RampScript™, which provides extensive new scripting capabilities for the BioScope Resolve® BioAFM. BioScope Resolve has set new standards for highest resolution AFM imaging with the first ever images of microvilli on live cells and by routinely resolving submolecular structures, such as the major and minor groove of DNA, while operating on an inverted microscope.

From Bruker Nano Surfaces and Metrology 11 Apr 2016

Ludwig, CRI launch Phase 1/2 trial of combination immunotherapy for advanced ovarian cancer

Ludwig Cancer Research and the Cancer Research Institute have launched a Phase 1/2 clinical trial of combination immunotherapy for advanced ovarian cancer. The international, multicenter trial is led by George Coukos, director of the Ludwig Institute for Cancer Research, Lausanne and Brad Monk, director of Gynecologic Oncology at St. Joseph's Hospital and Medical Center.

7 Apr 2016

Versatile Automated Microplate Sample Screening Applications

In this interview, News Medical speaks Tobias Pusterla, Ph.D from BMG Labtech about versatile automated microplate sample screening applications.

From BMG LABTECH GmbH 30 Mar 2016

Gleevec could be novel therapeutic agent for type 2 diabetes

The cancer treatment drug Imatinib, otherwise known as Gleevec is approved to treat various forms of cancer, mostly notably chronic myeloid leukemia (CML). However, researchers have stumbled onto another possible use for it, curing type 2 diabetes.

28 Mar 2016

Osteoporosis drugs market in the US estimated to cross US$ 4 billion by 2021

According to Pharmaion report, "United States Osteoporosis Drugs Market Opportunities, 2011 - 2021", the osteoporosis drugs market in the US is projected to cross US$ 4 billion by 2021.

26 Mar 2016

Microneedle-embedded patch delivers cancer immunotherapy directly to melanoma

Biomedical engineering researchers at North Carolina State University and the University of North Carolina at Chapel Hill have developed a technique that uses a patch embedded with microneedles to deliver cancer immunotherapy treatment directly to the site of melanoma skin cancer. In animal studies, the technique more effectively targeted melanoma than other immunotherapy treatments.

25 Mar 2016